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A B S T R A C TObjectives: Health care decision makers are increasingly concerned
about the value of chronic hepatitis B (CHB) treatments in China. This
analysis aims at estimating the relative value of entecavir as a first-
line option at treatment initiation and for different treatment dura-
tions from a holistic perspective. Methods: CHB was simulated by
using a Markov disease transition model with disease states based on
available natural history data. The model assumed 5-year treatment
duration with entecavir, lamivudine, telbivudine, and adefovir based
on published clinical data. The speed of disease progression varies by
viral load and hepatitis B ‘‘e’’ antigen status. Direct medical costs
included medication and management of liver complications. The
primary output was the estimated cost savings of entecavir per
patient per day versus the comparator. Results: For treatment dura-
tion of 5 years and a follow-up period of 30 years, entecavir treatment
was translated into specific patient benefit of an estimated cost saving
of $2.69 per day compared with no treatment. In addition, long-termsee front matter Copyright & 2013, International
r Inc.
.1016/j.vhri.2013.02.002
st: The authors have indicated that they have no
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0usage of entecavir resulted in daily $2.33 and $1.73 cost saving
compared with short-term usage (1-year and 2-year, respectively).
Among available treatment options in China, entecavir treatment
exhibited about $0.90 to $1.81 daily cost saving versus the compara-
tors. The detailed daily cost saving of entecavir is summarized as
follows—entecavir versus lamivudine: $1.81, entecavir versus telbivu-
dine: $0.90, entecavir versus adefovir: $2.02, and entecavir versus
generic adefovir: $1.37. Conclusions: Long-term usage of entecavir
exhibits the characteristics of a favorable CHB treatment, which
translates into economic value as opposed to either no treatment or
alternative strategies.
Keywords: adefovir, chronic hepatitis B, cost benefit, entecavir,
lamivudine, telbivudine.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Chronic hepatitis B (CHB) imposes a heavy financial burden on
the health care system in China. An epidemiology survey indi-
cated that approximately 93 million people carry hepatitis B
surface antigen (HBsAg) [1] while about 20 million of them are
active patients with CHB who experience sustained elevation of
hepatitis B virus (HBV) levels [2]. Patients with CHB are at a higher
risk of complicated liver diseases because persistent HBV infec-
tion is a significant cause of compensated cirrhosis (CC), decom-
pensated cirrhosis (DC), hepatocellular carcinoma (HCC), and
liver failure [3]. These complications of CHB would require addi-
tional health care resources and result in higher health care
expenses. Therefore, the ultimate aim of CHB treatment is to
prevent and reduce the morbidity and mortality of cirrhosis and
HCC [4]. While this can be achieved by eradicating HBV, it is rarelyfulfilled by currently available therapies [4]. Up to date, the most
realistic approach is to suppress HBV replication with nucleos(t)ide
analog (NA) antiviral therapies over the long term [4,5].
Four NAs—lamivudine, adefovir dipivoxil (adefovir), telbivu-
dine, and entecavir—have been in clinical application for the
treatment of CHB in China since 1999. The practice of antiviral
treatment, however, has not been well carried out in China to
date, in terms of medication coverage, choice of NAs, and
duration of treatment, based on 2009 market research report
[6]. By the end of 2010, less than 40% of the diagnosed patients
have been treated with NAs, whereas untreated patients can
progress to serious stages and incur more health care cost in the
future. In addition, although China CHB treatment guideline
suggested that stabilized hepatitis B ‘‘e’’ antigen (HbeAg)-positive
and HBeAg-negative patients could terminate antiviral therapies
after 2 years and 2.5 years of treatment, respectively [5], inSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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treatment [6]. Furthermore, there is a concern that inappropriate
therapies will cause disease complication and will consume
significant health care expenses in future. Currently, around
65% of the patients with CHB in China are treated by lamivudine
or adefovir, the clinically inferior drugs at cheaper prices. These
two drugs have exhibited lower virologic suppression and higher
incidences of resistance in clinical practices and have been
removed from first-line treatment in Europe, the United States,
and even other Asian countries [7–10]. Thus, it is pressing for the
relevant stakeholders to choose a therapy that would have long-
term clinical as well as economic benefits for both the patients
and the health care system.
We hereby employ a novel health-economics methodology,
the Perceived Value Assessment (PVA) method developed by
Monitor Deloitte (formerly Monitor Group) [11], to analyze the
long-term impact of treatment scenarios in China, aiming to
shed light on the relative economic value of each antiviral
therapy for the long run. This analysis translates clinical out-
comes, disease progression, and associated health care expense
into economic evaluation. The PVA methodology is innovative in
that it directly elucidates the cost difference (i.e., cost avoidance
or extra cost consumption) attributed to key clinical features of
the therapies. In more details, this analysis takes a daily average
over the cost difference attributable to key clinical outcomes due
to a proper long-term treatment—the cost difference is estimated
by a long-term cost-effectiveness analysis (i.e., a Markov model),
while the daily average of such cost difference fits into a short-
term budget impact analysis arena. Therefore, the PVA method-
ology can provide data on the value of the treatments (cost-
effectiveness) and generate information on financial estimates
(budget impact). In this study, we report PVA analysis on available
CHB treatment options at treatment initiation, different treatment
duration, and naive patient treatment with different NAs. The
results are illustrated as comparison against entecavir, the most
potent as well as the most expensive NA antiviral therapy in China.Methods
Treatment Options
Long-term economic evaluation of entecavir (0.5 mg/d), which has
the highest drug acquisition cost among these NA therapies, was
compared against other currently available treatment options in
China to indicate potential cost avoidance or extra costFig. 1 – CHB treatment options in China. (A) Comparison between
D) Among naive patients, comparison between 5-year treatmen
(LdT), and adefovir (ADV), respectively. (E) In entecavir treatmen
treatment (1 year or 2 year) with long-term treatment (5 year).
CHB, chronic hepatitis B.consumption (Fig. 1), including 1) no treatment (comparison A); 2)
short treatment duration (1-year and 2-year entecavir treatment,
comparison E); and 3) 5-year treatment with either lamivudine (100
mg/d, comparison B), telbivudine (600 mg/d, comparison C), or
adefovir (10 mg/d, comparison D) among naive patients.
A multilayered Markovian model (disease state transition
model) was used to simulate the natural progression of hepatitis
B, from CHB to CC to DC to HCC and so forth, and the effect of
treatment. A template model was initially developed by using
Excel 2007 (Microsoft Corporation, Redmond, WA) and was
adjusted manually to address the study’s specific needs. This
was combined with a detailed cost calculator for all components
in the natural history model and each treatment option.
The model assumes 11 and 10 disease states for HBeAg-
positive and HBeAg-negative patients with CHB, respectively
(Fig. 2). Based on results of the REVEAL study, patients move
through the states on an annual basis according to different
disease progression rates depending on the viral load [12,13]. A
weighted average of ‘‘uncontrolled’’ viral load average disease
progression rate based on REVEAL study is used for patients with
uncontrolled viral load [13], where uncontrolled viral load is
defined as HBV DNA above 300 copies/ml. All patients start
treatment at the uncontrolled viral load level. Natural disease
progression rate from the REVEAL study was used because of its
long-term observation period extending over 13 years among the
Asian subset. Data from Veenstra et al. was used to model
progression through CHB stages because no Asian studies were
available with adequate patient numbers. The progression
through stages was calibrated by using the REVEAL study
[13–15]. Rates of progression to end states were estimated by
using clinical trial data [16]. Mortality due to severe CHB disease
states was based on the published evidence [15,17–19], whereas
mortality rates similar to the general population of any country
were assumed for less severe CHB disease states (mild CHB,
HBeAg seroconversion, and HBsAg loss).
Time Horizon
Events and costs were modeled over a time horizon of 35 years in
yearly cycles, with the treatment duration of 5 years, due to the
availability of the current clinical data, and a 30-year follow-up
period to reflect the reality of long-term CHB management. The
5-year treatment includes all medication and treatment costs
associated with resistance and/or adverse events. For the follow-
up 30-year calculation, only management costs associated with
disease progression are incorporated.5-year entecavir (ETV) treatment versus no treatment. (B, C,
t with entecavir and with lamivudine (LAM), telbivudine
t in naive patients, comparison between short-term
Each treatment option includes a 30-year follow-up period.
Fig. 2 – Disease model structure. The above figure illustrates the multilayered Markovian model used to simulate the natural
progression of hepatitis B. A typical patient enters the simulation at the CHB disease state. From there, the patient either
remains in CHB or transitions into other potential disease states, including compensated cirrhosis, S loss, HCC, E sero
conversion, or out of the simulation altogether. The simulation model runs on an annual basis, so each patient may suffer
only one disease state per year. Depending on the disease state the patient ends up in at the end of each simulation run, the
patient transitions into other disease states or remains in the most recent state in the progressions indicated by the arrows
in Fig. 2. Single arrows represent transitions between health states; looped arrows indicate situations in which transition out
of a particular disease state is not 100% (i.e., a patient may remain in the disease state); and wide arrows represent
transitions to or from any state in the central column to a specific disease/end state (e.g., patients in disease states CHB, CC,
DC, liver transplant, or post–liver transplant may transition into peripheral neuropathy, myopathy, renal dysfunction, or
death). There are a total of 10 or 11 disease states, the latter of which applies only to hepatitis B ‘‘e’’ antigen (HbeAg)-positive
patients. The states include CHB disease states—1) CHB, 2) CC, 3) DC, 4) HCC, 5) liver transplant, 6) post–liver transplant; other
dynamic disease states—7) hepatitis B surface antigen (HBsAg) loss, 8) HBeAg seroconversion, and 9) creatinine kinase
elevation; 10) adverse effects; and 11) death. The state of E seroconversion (8) applies only to HBeAg-positive patients. CC,
compensated cirrhosis; CHB, chronic hepatitis B; DC, decompensated cirrhosis; HCC, hepatocellular carcinoma; S loss,
Hepatitis B surface antigen loss.
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confined by the availability and extent of such data. Most clinical
data are available for 5 or 6 years at most, not nearly as long as
the 35 years we intend to simulate, which is a key reason for the
5-year treatment duration and the 30-year follow-up time hori-
zon of the analysis. For the purpose of simulation, we assumed
that until year 35, the 5-year end-state patient clinical status is
preserved at sustained virologic suppression and resistance
across all comparisons.
Patient Population
Baseline patient population was set to most closely reflect the
average Chinese real-life population. Taking into consideration
the data availability, hypothetical average values were validated
through an advisory panel and tested by sensitivity analyses.
Patient population was composed of hypothetical cohorts of
HBeAg-positive and HBeAg-negative patients, with 1000 patients
in each cohort. The ratio of HBeAg-positive to HBeAg-negative
patients for the model was 60% to 40%, adjusted from 2009 China
survey [6] based on the expert panel meeting in 2011. It was
assumed that 12% of the patients at treatment initiation were at
‘‘cirrhosis’’ stage and the rest were at ‘‘CHB’’ stage [20].
Analysis of disease progression was run separately for the
HBeAg-positive and HBeAg-negative CHB patient population. The
average age of CHB treatment patients was assumed to be 35
years at treatment initiation, regardless of HBeAg status
[12,13,21–23]. This average age point did not differ greatly fromthat of the patients in the REVEAL study [12,13] or in the REALM
study carried out on the large Chinese patient cohort [23].
Clinical and Mortality Input
Key clinical data, such as viral load suppression and resistance
data, were taken from pivotal trials for lamivudine [24–27],
telbivudine [28–31], adefovir [32–36,53,54], and entecavir
[24–27,37–41], respectively, since 2002.
Mortality due to severe CHB disease states (DC and HCC) was
considered in the model on the basis of published evidence
[15,17–19]. For less severe CHB disease states (fibrosis and less
severe than fibrosis), the mortality rates were assumed to be
similar to those of the general population. All study assumptions
are summarized in Table 1.
The references selected were chosen on the basis of best data
available and data consistency. As such, Asian cohort data were
chosen over global data when such data were available and the
number of patients was meaningful.
Cost Inputs
The model assumed that each disease state has an associated
cost of care. This study considers only direct health care cost
such as the cost related to the diagnosis of the disease, laboratory
testing, drug acquisition, follow-up, and treatment for disease
complication. Drug costs were taken from a university-affiliated
hospital in Shanghai, which is representative of the overall price
Table 1 – Model assumption.
Variables Baseline
value (%)
Reference
Baseline characteristics
HBeAg-postivie:HBeAg-
negative (% of
population)
60%:40% [6] and Advisory
Board Meeting
in 2011
CHB stage 88%a [20]
Compensated cirrhosis
stage
12%a [20]
Treatment compliance
rate
70% [56]
Annual discount rate 5%
Annual disease progression rates—HBeAg-positive and HbeAg-
negative (uncontrolled:controlled viral load)
Progression from CHB to
compensated cirrhosis
7.0%b:1.9%c [13,15]
Progression from
compensated cirrhosis
to decompensated
cirrhosis
3.1%b:0.8%c [13,15]
Progression from
decompensated
cirrhosis to liver
transplant
2.6%b:0.7%c [13,15]
Progression from liver
transplant to
post–liver transplant
100.0%b:100.0%c
Assumption
Progression from HCC to
liver transplant
30.0%b:30.0%c [15]
Progression from CHB to
HCC
0.5%b:0.1%c [42]
Progression from
compensated cirrhosis
to HCC
2.2%b:2.2%c [43]
Progression from
decompensated
cirrhosis to HCC
2.2%b:2.2%c [43]
Annual death rates
Year 1 to 35d 0.1%–1.19% WHO 2009
Compensated cirrhosis
to death
4.9%d [18]
Decompensated
cirrhosis to death
19.0%d [17]
HCC to death 23.0%d [13,15]
Liver transplant to death 13.0%d [19]
Post–liver transplant to
death
2.5%d [19]
Annual histological improvement rates—on treatment—HBeAg-
positive and HBeAg-negative (uncontrolled:controlled viral load)
Histological
improvement rate
0.0%b:29.5%c [38]
CHB, chronic hepatitis B; HbeAg, hepatitis B ‘‘e’’ antigen; HBV,
hepatitis B virus; HCC; hepatocellular carcinoma; WHO, World
Health organization.
a No patients entered the model in decompensated cirrhosis/HCC/
liver transplant/post–liver transplant.
b Patients with uncontrolled viral load (HBV DNA level4300
copies/ml).
c Patients with controlled viral load (HBV DNA levelo300 copies/
ml).
d Assumptions for the population as a whole. The probability of
death was linked to liver histology and not to viral load.
Table 2 – Model cost input.
Disease state Cost
(RMB)
Source
CHB 14,632 [44], updated with China
National Healthcare Index
Compensated
cirrhosis
18,526 [44,45], updated with China
National Healthcare Index
Decompensated
cirrhosis
35,385 [44,45], updated with China
National Healthcare Index
Liver transplant 492,951y China Liver Transplant Registry
and China Advisory Board
Post–liver
transplant
72,212y China Liver Transplant Registry
and China Advisory Board
HBsAg loss 7,316z [45] and China Advisory Board,
China National Healthcare
Index
Hepatocellular
carcinoma
80,176 [45], updated with China
National Healthcare Index
Death 0§ –
CHB, chronic hepatitis B; EASL, European Association for the Study
of the Liver; HbsAg, hepatitis B surface antigen.
 Calculated from cirrhosis total cost [44], assuming cost of
compensated:cost of decompensated ¼ 1:1.91 and patient ratio is
assumed to be 1:1 based on Hu and Chen [45].
y Calculated and updated liver transplant surgery cost and post–-
liver transplant cost with China Liver Transplant Registry and
China Advisory Board.
z Assume about 50% of CHB based on EASL guideline [10].
§ Only direct medical cost of disease state is considered.
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were updated to 2010 by using China national health care index
from China Statistics Bureau (Table 2).
For the management of resistance, additional treatment costs
included clinical assays for mutation detection, extra examina-
tions, as well as the salvage therapy drug cost incurred during the
5-year treatment period in the model. As recommended in the
treatment guideline or practiced in the clinical trials, it is
suggested that patients with lamivudine resistance or telbivudine
resistance add adefovir to the treatment regime and that patients
with adefovir resistance switch to entecavir, though actual
combination options may vary in practices in the real world.
For drug-related adverse events, the model assumed that safety
and tolerability of entecavir were similar to those of lamivudine
[13,24], and neither drug has requirement for renal monitoring
based on entecavir summary of product characteristics 2009.
However, patients receiving telbivudine may be at the risk of
muscle diseases with concomitant elevation of creatine kinase
concentration, which requires creatine kinase/serum phosphate
monitoring and treatment [46–48]. Patients receiving adefovir may
be at the risk of renal dysfunction and must monitor the creatinine
level regularly during the treatment period [47,48].
Costs were discounted to net present value at a discount rate
of 5%, taking into consideration that the model simulates current
into the future. All costs were inflated to 2010 prices by using
China health care consumer prices indices and converted to US
dollars. The exchange rate used was US $1 ¼ 6.349 RMB. All costs
were calculated from the holistic point of view, with both
patients’ out-of-pocket cost and payer’s cost in consideration.Model Outputs
The primary outcome measures were per-patient cost per day of
treatment of entecavir compared with no treatment, short-term
Table 3 – Utility scores and assumptions of the
disease states.
Disease state Utility
score
Source and assumption
F0/F1 0.55 [49], assuming F0/F1:F2/F3/F4 ¼
1.1, based on European PVA
Advisory Board
F2/F3/F4 0.50 [49], assuming F0/F1:F2/F3/F4 ¼
1.1, based on European PVA
Advisory Board
4F4 to
compensated
cirrhosis
0.57 [49]
Decompensated
cirrhosis
0.26 [49]
Liver transplant 0.41 [49]
Post–liver
transplant
0.55 [49]
Hepatocellular
carcinoma
0.31 [49]
S loss 0.71 [49], assuming same as healthy
population
Seroconversion 0.71 [49], assuming same as healthy
population
Death 0 –
PVA, Perceived Value Assessment; S loss, Hepatitis B surface
antigen loss.
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over a follow-up period of 30 years. The daily overall treatment
cost accounted for drug acquisition cost and clinical differences
between treatment options. In comparison with no treatment
and short-term treatment, clinical events considered were HBsAg
loss, HBeAg seroconversion, fibrosis, CC, DC, HCC, liver trans-
plantation, and post–liver transplantation. In comparison with
other antiviral therapies, clinical attributes considered were
virologic suppression, long-term resistance associated with addi-
tional monitoring and pharmacotherapy cost, long-term safety
associated with additional monitoring and treatment, and sero-
logical responses. In the PVA analysis, cost avoidance outputs
across all NA comparisons are disaggregated and linked to each
clinical attribute of the antiviral treatment. Thus, the contribu-
tion of each clinical attribute to overall cost savings can be
quantified and presented.
Costs avoided for each of the clinical events listed above over
the 35-year period were calculated to compare entecavir with no
treatment, short-term treatment, or other antiviral therapies and
then recalculated to estimate the ‘‘cost avoidance per day of
treatment’’ (cost avoidance C total days on treatment). Costs
avoided were calculated for each event type avoided as (total
number of events avoided  the cost of event C days on treat-
ment). The costs avoided were applied to the daily dose acquis-
ition cost for each treatment to determine the perceived cost of
entecavir relative to no treatment, short-term treatment, or other
antiviral therapies. Costs are presented in 2010 values and as the
proportion of entecavir acquisition cost avoided by the use of
entecavir relative to the comparators. Exchange rate used was
the same as the rate used for cost inputs.
The conventional cost-utility analysis accounts for cost and
health effects separately, and it is necessary to discount both. On
the contrary, the primary output of the PVA analysis is in terms of
daily cost only, which is already a function of all health effects.
As such, discounting all future costs inherently discounts all
future health effects as well. If both the health effects that
contribute to cost and the resulting cost were discounted, it
would result in double-discounting error. Therefore, it was
unnecessary to separately discount clinical outcome in the PVA
analysis.
Utility Analyses
Utility analyses were conducted by calculating quality-adjusted
life-years (QALYs) of each treatment option over the entire treat-
ment and follow-up time horizon. The utility score of mainland
Chinese population for each health state was based on the study
conducted by Levy et al. [49] and assumptions listed in Table 3.
Sensitivity Analyses
Both univariate and multivariate analyses (Tornado and Monte
Carlo simulations) were conducted by Crystal Ball (Oracle Corpo-
ration, Redwood Shores, CA) to test the robustness of model
outcome, given the uncertainty around certain clinical and cost
inputs. The Tornado analysis investigated the effects of varying
one key input at a time, and then ranked the influence of
each variable. The resulting Tornado analyses were used to
identify the key inputs generating the biggest variation in model
outputs. These inputs, along with other key inputs with some
uncertainty, were subsequently used for probabilistic sensitivity
analyses.
Key input variables that were given a variation range were
discount rate, all unit costs and disease state costs, clinical
profiles including virologic suppression efficacy and resistance,
baseline characteristics such as HbeAg-positive to HbeAg-
negative ratio, and compliance rate.Results
Entecavir Treatment versus No Treatment
If CHB were left untreated, the disease could advance to serious
complications such as DC, HCC, and even death. With optimal
antiviral treatment, disease progression can be slowed down or
even reversed through rapid and sustained viral load suppres-
sion, high genetic barrier and long-term protection against
resistance, and long-term treatment safety with minimal inci-
dence of associated adverse event. Among CHB antiviral NA
therapies available in China, entecavir exhibits the optimal
profile in all clinical aspects. This was confirmed by observing
the patient distribution after the modeling period.
Simulation of disease progression over 35 years showed that by
the end of year 35, the natural course of CHB will cumulatively
lead 84% of the 1000 patients to serious stages including death,
liver transplant, and HCC, 10% to medium stages including DC and
CC, and 7% to CHB (Fig. 3A). In contrast, with a 5-year treatment
with entecavir and 30-year follow-up, 47%, 5%, and 48% of the
patients ended in serious, medium, and mild stages, respectively
(Fig. 3A). These figures strongly suggest that treatment with
entecavir would significantly decelerate the disease progression
and avoid the expenses in the management of serious liver
diseases. As a result (Fig. 3B), over the 35 years, each pill of
entecavir could avoid US $8.69 for expenses in clinical manage-
ment, which fully outweigh the acquisition cost of US $6.00. This
indicates that entecavir could avoid US $2.69 per day compared
with no treatment (95% confidence interval [CI] US $1.42–US $4.71).
To apply this to real-life setting, based on the 2009 market
research [6], there are about 2.37 million patients who have been
diagnosed with CHB but who were never treated with any
antiviral therapy in China. Treatment with entecavir would
prevent these patients from progressing to serious liver compli-
cations and avoid $2.5 billion per year for the country in total
based on the model projection.
Fig. 3 – PVA model result—entecavir (ETV) versus no treatment and alternative therapy. (A) Comparison of 35-year cumulative
incidence rates between ETV treatment and no treatment. (B) Economic analysis of ETV treatment versus no
treatment—costs of treating a patient with chronic hepatitis B per day avoided by 5 years of ETV treatment and 30-year
follow-up compared with no treatment with 30-year follow-up. (C) Economic analysis of ETV treatment versus lamivudine
(LAM) treatment—costs of treating a patient with chronic hepatitis B per day avoided by 5 years of ETV treatment and 30-year
follow-up compared with LAM treatment. (D) Economic analysis of ETV treatment versus telbivudine (LdT) treatment—costs
of treating a patient with chronic hepatitis B per day avoided by 5 years of ETV treatment and 30-year follow-up compared
with LdT treatment. (E) Economic analysis of ETV treatment versus adefovir (ADV) treatment—costs of treating a patient with
chronic hepatitis B per day avoided by 5 years of ETV treatment and 30-year follow-up compared with ADV treatment. (F)
Economic analysis of ETV treatment versus generic ADV treatment—costs of treating a patient with chronic hepatitis B per
day avoided by 5 years of ETV treatment and 30-year follow-up compared with generic ADV treatment. CC, compensated
cirrhosis; CHB, chronic hepatitis B; DC, decompensated cirrhosis; HbeAg, hepatitis B ‘‘e’’ antigen; HCC, hepatocellular
carcinoma; LT, liver transplant; PVA, Perceived Value Assessment; USD, US dollars. A multivariate sensitivity analysis was
performed by using the Crystal Ball (Oracle Corporation, Redwood Shores, CA), and the range of impact on the resulting cost
avoidance is noted in each of the above figures. Crystal Ball software performs multivariate sensitivity analysis through
assigning 1000 randomized variables to model input assumptions. The analyses included cost avoidance results within 95%
confidence intervals and were based on adjustments to 35þ key model input assumptions such as the following:
Variables Baseline value Sensitivity input range
Baseline characteristics
HBeAg-positive:HBeAg-negative (% of population) 60%:40% 50%:50%– 60%:40%
CHB stage 88% 83%–100%
Treatment compliance rate 70% 64%–74%
Annual discount rate 5% 3%–7%
Economic inputs
Disease state costs Please refer to Table 2 10%
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The result of the multivariate sensitivity analysis indicated that the impact of the annual discount rate was the greatest among all input
variables. As such, in addition to presenting the above results for discount rate ranging from 3% to 7%, the below table illustrates the
results of a multivariate analysis based on 0% discount rate with 95% confidence level.
Treatment comparison Cost avoidance at
discount rate ¼ 5%
(US $)
Cost avoidance at discount
rate ¼ 3%–7% (US $)
Cost avoidance at
discount rate ¼ 0%
(US $)
Entecavir treatment vs. no treatment 2.69 1.42–4.71 9.42
Long-term entecavir treatment vs.
short-term entecavir treatment
2.33 (1 y); 1.73 (2 y) 1.04–4.16 (1 y); 0.54–3.42
(2 y)
9.62 (1 y); 8.76 (2 y)
Long-term entecavir treatment vs.
lamivudine treatment
1.81 0.68–2.57 6.58
Long-term entecavir treatment vs.
telbivudine treatment
0.90 0.25–1.40 3.69
Long-term entecavir treatment vs.
adefovir treatment
2.02 (branded); 1.37
(generic)
0.98–2.87 (branded);
0.35–2.21 (generic)
6.60 (branded); 5.98
(generic)
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Treatment
A long-term treatment is able to suppress the viral replication
without viral rebounding and thus retard the disease progression
for a longer term. In contrast, a short-term treatment may suffer
from the setback of viral rebound after halting treatment. As a
result, 5-year entecavir treatment would outweigh the drug
acquisition cost and could avoid US $2.33 (95% CI US $1.04–US
$4.16) and US $1.73 (95% CI US $0.54–US $3.42) per day compared
with 1-year and 2-year entecavir treatment, respectively.Table 4 – QALYs of CHB treatment options.
Treatment option QALYs
5-y entecavir 16.2
5-y telbivudine 15.6
5-y lamivudine 15.2
5-y adefovir 14.8
2-y entecavir 14.4
1-y entecavir 13.2
No treatment 11.6
CHB, chronic hepatitis B; QALY, quality-adjusted life-year.
 Each treatment option includes a 30-y follow-up period.Long-Term Entecavir versus Lamivudine, Telbivudine, and
Adefovir
As the antiviral exhibited different clinical profiles with regard to
virologic suppression, long-term resistance, long-term safety,
and serological responses, the comparison of a 5-year treatment
of entecavir with other antivirals plus 30-year follow-up was
conducted for these four parameters. Simulation indicated that a
superior clinical profile in any of the four aspects leads to cost
savings. The clinical profile of entecavir results in cost saving in
at least three of the four aspects for each antiviral compared
against, overcoming its higher drug acquisition cost.
Compared with lamivudine (Fig. 3C), entecavir would reduce
management cost with regard to virologic suppression, long-term
resistance, and serologic responses. Even with a premium of US
$3.51 per pill over lamivudine, entecavir’s clinical profile could
avoid US $5.48 in health care management and reduce its
perceived price to US $0.52, leading to a cost avoidance of US
$1.81 per day compared with lamivudine (95% CI US $0.68–US
$2.57). The greatest cost savings were attributed to virologic
suppression at US $3.26 and long-term resistance at US $2.16.
Compared with telbivudine (Fig. 3D), entecavir reduces man-
agement cost with regard to virologic suppression, long-term
resistance, and long-term safety. Thus, entecavir overcomes its
price premium and results in a cost avoidance of US $0.90 per day
compared with telbivudine (95% CI US $0.25–US $1.40). Greatest
cost savings were attributed to virologic suppression at US $1.76
and long-term resistance at US $1.04.
Compared with adefovir, entecavir reduces the management
cost in all four aspects mentioned above. Thus, entecavir over-
comes its price premium and results in cost avoidance of US$2.02 (95% CI US $0.98–US $2.87) and US $1.37 (95% CI US $0.35–US
$2.21) per day compared with branded adefovir (Fig. 3E) and
generic adefovir (Fig. 3F), respectively. The greatest cost savings
were attributed to virologic suppression at US $3.29, and long-
term safety at US $0.83 and US $0.98 for branded and generic
adefovir, respectively.
Utility Analyses
Among all the treatment options, 5-year entecavir treatment
with 30-year follow-up achieved the highest QALY (Table 4),
indicating that it is the treatment option that brings the highest
clinical benefits to the patients.
Sensitivity Analyses
Multivariate sensitivity analysis with predefined input variation
ranges indicated that the variable sensitivity of the annual
discount rate for net present value calculation exceeded that of
clinical inputs, cost inputs, or any other inputs. As observed by all
the 95% CIs indicated above, entecavir achieved cost avoidance
despite a variance of 3% to 7% annual discount rate (default value
5%). Univariate sensitivity analysis with uniform input variation
ranges indicated that drug dosage compliance rate was the most
sensitive variable. Entecavir achieved cost avoidance despite
a 10% variance in compliance rate (in comparison with no
treatment, daily cost avoidance was US $3.65 when the compli-
ance rate was down by 10% and US $1.91 when up by 10% from
the default value of 70%, respectively).
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It has long been a sought-after question on what is the most cost-
beneficial therapy for patients with CHB. Clinical practices have
shown that a therapy with potent viral load suppression, high
genetic barrier for resistance, and long-term safety profile would
achieve optimal clinical results. The long-term economic benefits
associated with the clinical benefits, however, have rarely been
evaluated until now [50]. Our analysis aims to answer this
question by evaluating the cost benefits of CHB treatment options
available in China by employing a novel methodology, the PVA,
which translates clinical attributes to cost savings. The study
demonstrates that the clinical benefits of entecavir lead to
certain amounts of health care cost savings, which offset its
acquisition cost against all other treatment options. Entecavir is
thereby the most cost-saving therapy in the long-term compared
with other treatment options including no treatment, short-term
entecavir treatment, or long-term treatment with other antiviral
therapies. Preliminary second-line analyses of lamivudine and
adefovir suboptimal responders switching to entecavir also
resulted in cost avoidance, but these results were reserved
because they were loosely based on indirect comparison data
from studies of less than 2 years [51].
However, entecavir is not without drawbacks because it would
take several years beyond the short-term to achieve cost avoid-
ance breakeven point against other treatment options due to its
higher acquisition cost. Entecavir reaches the breakeven point
against lamivudine, telbivudine, and adefovir posttreatment ini-
tiation at year 6, year 11, and year 12, respectively. It would be
challenging for entecavir to achieve short-term cost saving com-
pared with these treatment options. Nevertheless, cost analysis of
lifelong chronic diseases such as CHB should be focused on the
long-term cost benefit, and entecavir is clearly advantageous in
the long-term because it continues to accumulate greater cost
avoidance after the breakeven point. At year 35 posttreatment
with 1000 patients, entecavir would have gained a total cost
avoidance of 11 million, 5 million, and 13 million RMB against
lamivudine, telbivudine, and adefovir, respectively, based on the
current model. This may imply that because cost benefit increases
with time, entecavir should be strongly recommended to subpo-
pulation of younger age that faces a longer treatment period.
Entecavir’s clinical attributes are also translated to improved
quality of life among the patients. We calculated the QALYs of the
patients for 35 years, including the treatment period and 30-year
follow-up. Results show that 5-year entecavir treatment achieves
16.2 QALYs, the longest among all the comparables. In addition,
because a long-term entecavir treatment consumes a smaller
amount of health care expenditures in total, the incremental
cost-effectiveness ratio (ICER) is negative, which means that
long-term entecavir treatment has dominant cost-effective
advantages over other treatment options, further supporting
our PVA analysis. These results are consistent with the conclu-
sions in other cost-effectiveness analysis articles [18,52].
Compared with the prevalent ICER-based approach for cost-
effectiveness evaluation, the PVA analysis has certain advan-
tages. First, the PVA method directly elucidates the cost differ-
entiation on a daily basis and is easier to understand for people
of all walks of life. In addition, because there is no official
threshold for an acceptable ICER in China, it is more challenging
to judge the degree of cost-effectiveness with the ICER method.
Second, PVA is especially useful for the scenario of negative ICER/
QALY value because PVA is able to quantify the cost avoidance
of the dominant therapy. In contrast, though ICER could be used
to express the extra cost required for an extra QALY, it is difficult
to quantify when cost is avoided while extra QALY is gained.
Last but not the least, the PVA method directly quantifies theeconomic benefit for the corresponding clinical attribute and
ranks the importance of clinical outcomes of each therapy. Thus,
PVA analysis would help all the payers, physicians, and patients
to make well-informed choices on cost-effective therapies.
Such advantages, however, do not exempt the PVA method
from the limitations that other cost-effectiveness analyses were
unsuccessful in overcoming.
First, the 35 years’ time horizon is based on 5-year treatment
duration and 30-year follow-up duration due to lack of clinical
data that extends beyond 5 to 6 years. Economic impact becomes
more meaningful and comparable under long-term observation,
which is even more applicable to chronic diseases such as CHB.
As such, the 5-year results were extrapolated to the entire
simulation period. Such a practice is not uncommon in health-
economics assessment of chronic diseases, including CHB
[15,17,21,42]. Instead of assuming treatment termination, we
assumed that the 5-year end-state patient viral load status is
preserved until year 35 for the purpose of simulating the long-
term economic effect of the 5-year treatment. Hence, clinical
events associated with treatment termination, such as viral load
rebound and seroconversion rebound, were neglected.
Second, the PVA analysis neglects the cost of social burden
and considers direct medical costs only. Hence, the lower death
rate would undermine the cost benefits of entecavir because no
disease state cost is assumed for incidence of death. Entecavir, a
therapy with a lower death rate, would apparently incur more
health care cost than one with a higher death rate and lead to
lower cost benefits.
Third, the PVA analysis does not take into account the
possible deviation in reality from treatment guideline in China
regarding treatment combination options for lamivudine, telbi-
vudine, or adefovir resistance. Because of lack of data accurately
reflecting the extent of such deviations, these factors were
excluded from the analysis.
Despite these limitations, long-term entecavir treatment of
CHB exhibits cost benefits over other antiviral therapies, partic-
ularly when the treatment is initiated at an early stage and the
therapy is sustained for a long period of time to curb the viral
replication and the disease progression. A significant disparity,
however, exists between the most cost-beneficial practice and
the current practice in China where only a small fraction of
patients with CHB are treated by entecavir and the treatment
lasts less than 1 year. Such a disparity could lead to skyrocketing
health care costs in the foreseeable future to rescue the patients
with CHB who advance to serious diseases because of insufficient
or inappropriate treatment. Therefore, it is hoped that our study
would shed light on the fact that there is an urgent need to
implement a cost-beneficial therapy and motivate the payers to
support the optimal therapy in the country.
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